Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

ADVERTISEMENT

Monkeypox (Mpox) Vaccines: WHO initiates EUL procedure  

In view of serious and growing outbreak of monkeypox (Mpox) disease in the Democratic Republic of the Congo (DRC) that has now spread outside the country and detection of the new strain that first emerged in September 2023 outside DRC, WHO has invited manufacturers of mpox vaccines to submit an Expression of Interest for Emergency Use Listing (EUL) including data to prove that the vaccines are safe, effective, of assured quality and suitable for the target populations. 

The EUL procedure is an emergency use authorization process, specifically developed to expedite the availability of unlicensed medical products like vaccines that are needed in public health emergency situations. EUL approval will improve vaccine availability particularly for resource constrained settings which have not yet issued their own national regulatory approval. The EUL also enables partners including Gavi and UNICEF to procure vaccines for distribution. 

Monkeypox virus (MPXV) is a double-stranded DNA virus belonging to genus Orthopoxvirus along with vaccinia virus (VACV) and variola virus (VARV). It is closely related to smallpox, the deadliest virus in history responsible for unparalleled devastation of human population in the past centuries. With the complete eradication and subsequent cessation of smallpox vaccination programme (which had provided some cross protection against monkeypox virus as well), the current human population has much reduced levels of immunity against this group of viruses. This reasonably explains the current rise and spread of monkeypox virus from its endemic regions in Africa.  

Mpox is a viral illness caused by the monkeypox virus. Mpox can be transmitted to humans through physical contact with infected persons, or with contaminated materials, or with infected animals.  

Mpox vaccines currently in use:  

For healthy adults, non-replicating (MVA-BN), minimally replicating (LC 16) or replicating vaccinia-based vaccines (ACAM2000) are appropriate.  

MVA-BN is a 3rd generation mpox vaccine administered as two-dose subcutaneous injection given at least 4 weeks apart. Both 1 and 2 doses of MVA-BN are highly effective at preventing mpox. 

LC16 and ACAM2000 are single dose mpox vaccine.  

*** 

References:  

  1. WHO Press release – WHO invites mpox vaccine manufacturers to submit dossiers for emergency evaluation. Published 09 August 2024. Available at https://www.who.int/news/item/09-08-2024-who-invites-mpox-vaccine-manufacturers-to-submit-dossiers-for-emergency-evaluations  
  1. WHO. Vaccines and immunization for monkeypox: Interim guidance, 16 November 2022. Available at https://iris.who.int/bitstream/handle/10665/364527/WHO-MPX-Immunization-2022.3-eng.pdf  
  1. Pischel L., et al 2024. Vaccine effectiveness of 3rd generation mpox vaccines against mpox and disease severity: A systematic review and meta-analysis. Vaccine. Available online 21 June 2024. DOI: https://doi.org/10.1016/j.vaccine.2024.06.021  

*** 

Related articles  

Virulent Strain of Monkeypox (MPXV) Spread Through Sexual Contact (20 April 2024) 

Monkeypox virus (MPXV) variants given new names (12 August 2022) 

Will Monkeypox go Corona way? (23 June 2022) 

*** 

SCIEU Team
SCIEU Teamhttps://www.ScientificEuropean.co.uk
Scientific European® | SCIEU.com | Significant advances in science. Impact on humankind. Inspiring minds.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Most Popular Articles

COVID-19: ‘Neutralising Antibody’ Trials Begins in the UK

University College London Hospitals (UCLH) has announced neutralising antibody...

Story of Coronaviruses: How the ‘’novel Coronavirus (SARS-CoV-2)’’ May Have Emerged?

Coronaviruses are not new; these are as old as...

A New Antibody Approach to Fight Ovarian Cancer

A unique immunotherapy-based antibody approach has been developed which...
- Advertisement -
93,385FansLike
47,372FollowersFollow
1,772FollowersFollow
30SubscribersSubscribe